Clozaril Articles
Azur and Elan to co-develop once-daily clozapine
17 November 2008
Barr Labs challenges FazaClo patents
1 September 2008
Azur Pharma completes $48M financing and FazaClo buy
13 August 2007
Acadia initiates Ph IIb trial of ACP-104
2 July 2007
FDA approves Avanir's new form of clozapine
11 June 2007
Lilly maintains cost-effectiveness of Zyprexa
11 December 2006
Avanir to buy Alamo Pharma for $29M
29 May 2006
Drug studies "biased" towards sponsors
24 April 2006
Teva gets clearance for clozapine in USA
9 May 2005
Corcept's Corlux shows good weight loss result
25 April 2005
Florida sues three firms for Medicaid "fraud"
18 April 2005
Paul Duffy joins Alamo as exec VP
23 August 2004
US appro for Alamo/Cima's Fazaclo
15 March 2004
Pharmacogenetic testing and the development of new drugs
13 October 2003
Lilly receives product labeling letter from FDA
29 September 2003
Swiss OK for new use of Novartis' Leponex
21 July 2003
Caraco expects $35M revenues in 2003
24 February 2003
Zyprexa - placebo-like levels of EPS
19 August 2002
Novartis adds warning to Clozaril labeling
4 March 2002
Stock Commentary - Europe
4 March 2002
Protarga's Clozaprexin is "safer, more effective"
24 January 2001
Call for FDA to take action on generic clozapine issue
7 November 2000
IVAX defends generic clozapine products after WSJ report
26 October 2000
Eli Lilly's Evista shows efficacy in osteoporosis treatment
19 August 1999
US doctors to justify costly antipsychotics
2 June 1999
Novartis' iloperidone in Phase III in USA
21 January 1999
Novartis Restructures After Disappointing First Half
1 September 1998
Novartis Starts Phase III Iloperidone Trials
20 August 1998
US Psychiatric Drug "Price-Gouging:" Report
17 July 1998
High Hopes For HMR's Novel Antipsychotic
15 July 1998
Cortex' Ampalex In Schizophrenia
15 June 1998
FDA Approves IVAX Generic Clozapine
4 December 1997
Novartis Licenses Iloperidone From Titan
21 November 1997
Clozaril Reduces Suicide Rate
30 October 1997
Mental Health Study Slams Managed Care
24 September 1997
Zeneca's Seroquel Debuts In UK For Schizophrenia
24 September 1997
Thalidomide Closer To US Market For Leprosy
10 September 1997
Zeneca's Seroquel Gains UK Approval, Its First
5 August 1997
New Clozapine Monitoring Schedule
17 July 1997
Zeneca's Seroquel Nears Market Approval
16 July 1997
Ampalex In Schizophrenia
30 May 1997
Scotia Progresses In Schizophrenia
23 April 1997
Bid To Change California Mental Illness Drug Policy
9 April 1997
1996 A Demanding Year For Novartis
19 March 1997
Russian Drug Output Fails To Meet Demand
27 January 1997
Product News In 1996 Dominated By CNS
23 December 1996
Novartis Partners 9 Months Figures Disappoint
28 October 1996
Lilly Launches Zyprexa In Its First Markets
21 October 1996
Zyprexa Gains 1st Approvals In USA/EU For Schizophrenia
7 October 1996
Janssen Pharma's Futurum For Schizophrenia
9 September 1996
Zeneca Files First European Seroquel Dossier
19 August 1996
First Market Launch of Serdolect
15 July 1996
Ziprasidone May Have Unique Neuroleptic Activity
8 July 1996
First Appro Of Sertindole In UK; Launch Imminent
1 July 1996
....Nutrition Downturn And Currency Holds Sandoz Back
29 April 1996
Atypical Antipsychotic Cuts Schizophrenia Costs
8 April 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Novartis Pipeline: A Good Fit But Cuts Are Expected
18 March 1996
Phase III Data With Lilly's Olanzapine
8 January 1996
Zeneca Reveals Typically Strong Pipeline
18 December 1995
Sandoz 9 Months Sales up 6%
6 November 1995
Zeneca's Phase III Data Support Seroquel Efficacy
16 October 1995
Lilly Submits Olanzapine For Approval Worldwide
2 October 1995
Sandoz Demergers To Focus On Pharmaceuticals
3 April 1995
Clozapine Reduces Suicide In Schizophrenia
20 February 1995
Sandoz' 1994 Sales Advance 11%
23 January 1995
FDA Letter On Clozapine Trials
23 January 1995
3% Increase In Sales For Sandoz
31 October 1994
Clozapine Can Reduce Suicide Risk
24 October 1994
Improvement At Sandoz in 1994 1st Half
12 September 1994
SOLID VOLUME GROWTH HELPS SANDOZ' SALES
25 July 1994
Phase II Results With Lilly's Olanzapine
18 July 1994
PHASE II RESULTS WITH ZENECA'S SEROQUEL
4 July 1994
SLOW QTR AT SANDOZ AS PHARMA SALES DECLINE
25 April 1994
PHARMA SALES DRIVE SANDOZ IN 1993
31 January 1994
HUNGARIAN FIRMS SUE OVER BLACK MARKET
29 November 1993
STUDY SAYS CLOZARIL USE SAVES MONEY
15 November 1993
ASTRA'S ROXIAM HITS TOXICITY TROUBLE
8 November 1993
SUSTAINABLE EARNINGS GROWTH FOR SANDOZ
16 August 1993
SANDOZ POSTS STRONG NET INCOME
26 July 1993
RISPERDAL LAUNCHED IN UK
31 May 1993
US FDLI PHARMACEUTICAL UPDATE MEETING
31 May 1993
SCHIZOPHRENIA MARKET WORTH $2 BILLION BY 2002
17 May 1993
RECOMMENDATION FOR RISPERDAL APPROVAL
17 May 1993
TOKYO STOCK COMMENT
26 April 1993
FURTHER CLUES TO CLOZARIL ACTION
26 April 1993
NEUROPHARMACEUTICAL MARKET IN USA
19 April 1993
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
